- Home
- CNSP vs GTBP Comparison
CNSP vs GTBP Comparison
Compare CNSP & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | GTBP |
|---|---|---|
| Founded | 2017 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 2.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNSP | GTBP |
|---|---|---|
| Price | $7.90 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 1.6M |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $0.54 |
| 52 Week High | $114.00 | $4.10 |
Technical Indicators
Market Signals| Indicator | CNSP | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 47.17 |
| Support Level | $6.11 | $0.58 |
| Resistance Level | $8.10 | $0.82 |
| Average True Range (ATR) | 0.48 | 0.07 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 84.42 | 32.15 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.